| Literature DB >> 30011891 |
Mensiena B G Kiewiet1, Marijke M Faas2, Paul de Vos3.
Abstract
Immunomodulatory protein hydrolysate consumption may delay or prevent western immune-related diseases. In order to purposively develop protein hydrolysates with an optimal and reproducible immunomodulatory effect, knowledge is needed on which components in protein hydrolysates are responsible for the immune effects. Important advances have been made on this aspect. Also, knowledge on mechanisms underlying the immune modulating effects is indispensable. In this review, we discuss the most promising application possibilities for immunomodulatory protein hydrolysates. In order to do so, an overview is provided on reported in vivo immune effects of protein hydrolysates in both local intestinal and systemic organs, and the current insights in the underlying mechanisms of these effects. Furthermore, we discuss current knowledge and physicochemical approaches to identify the immune active protein sequence(s). We conclude that multiple hydrolysate compositions show specific immune effects. This knowledge can improve the efficacy of existing hydrolysate-containing products such as sports nutrition, clinical nutrition, and infant formula. We also provide arguments for why immunomodulatory protein hydrolysates could be applied to manage the immune response in the increasing number of individuals with a higher risk of immune dysfunction due to, for example, increasing age or stress.Entities:
Keywords: Toll-like receptor; bioactive peptide; functional foods; immunomodulation; protein hydrolysate
Mesh:
Substances:
Year: 2018 PMID: 30011891 PMCID: PMC6073538 DOI: 10.3390/nu10070904
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1The process of protein hydrolysis and its products. (A) chemical reaction of protein hydrolysis; (B) different hydrolysates serve different purposes.
Overview of hydrolysates and their immune effects.
| Hydrolysate/Peptide | Enzyme/Treatment | Immune Effects | Species | Reference |
|---|---|---|---|---|
| Casein hydrolysate diet (200 g/kg casein, TD99482, Harlan-Teklad Custom Research, Madison, WI, USA | Not applicable (NA) | Reduction of autoimmune diabetes by 50%, decreased lactulose/mannitol ratio, decreased serum zonulin levels, increased ileal TEER, altered ileal mRNA expression of Myo9b, claudin-1, and claudin-2. | Diabetes prone BB rat | [ |
| Casein hydrolysate (20% of diet Pancase STM (Sensient Flavours, Strassbourg, France) or NutramigenTM (Mead Johnson Nutrition, Zeeland, MI, USA)) | NA | Reduction of autoimmune diabetes, decreased lactulose/mannitol ratio, increased ileal IL-10 levels, beneficial gut microbiota changes (increased | Diabetes prone BB rat | [ |
| β-CN(94-123) from commercial yoghurt | NA | Enhanced numbers of goblet and Paneth cells in the small intestine, increased expression of Muc2, Muc4, lysozyme, and rdefa5. | rat | [ |
| Yoghurt or Milk Fermented by | Increased cell proliferation and villous area in the proximal intestine, hypertrophy and hyperplasia of Paneth and goblet cells. | mouse | [ | |
| Milk fermentation products of | Enhanced expression of calcineurin in the small intestine, upregulated IL-2 and TNF production, increased number of mucosal mast cells and goblet cells | mouse | [ | |
| Egg yolk digests | Pepsin | Increase of the IL-6 secretion by small intestinal epithelial cells, increase in IgA+ cells, orchestrating the Th1/Th2 response. | mouse | [ |
| Common carp egg hydrolysate | Pepsin, alcalase | Increase of secretory immunoglobulin A in the gut. | mouse | [ |
| Yellow field pea hydrolysate | Thermolysin | Increased number of IgA+ cells in the small intestine lamina propria, accompanied by an increase in the number of IL-4+, IL-10+, and IFNγ + cells. | mouse | [ |
| Fermented pacific whiting protein | Yeast | Enhanced phagocytic activity of peritoneal macrophages, increased number of IgA+ cells, and increased IL-4, IL-6, IL-10, IFNγ, and TNFα levels in the small intestine lamina propria | mouse | [ |
| Shark protein hydrolysate PeptibalTM (innoVactiv Inc) | Trypsin and chymotrypsin | Increase of small intestinal immunoglobulin A-producing cells and intestinal IL-6, TNFα, TGFβ, and IL-10 | mouse | [ |
| Peptide fraction from | Lactobacillus Helveticus | Increased intestinal and serum IgA levels, increase in the number of IgA-secreting B lymphocytes in the intestinal lamina propria, stimulation of Th2 response (IL-4 vs. IFNγ) | mouse | [ |
| κ-casein–derived glycomacropeptide | NA | Decreased body weight loss, decreased anorexia, colonic damage, a reduction in colonic alkaline phosphatase activity, IL-1, trefoil factor 3, and iNOS mRNA levels. | Rat (TNBS induced colitis) | [ |
| β-Casein hydrolysate | Cell envelope-associated proteinase of Lactobacillus delbrueckii ssp. lactis CRL 581 | Decreased mortality rates, faster recovery of initial body weight loss, less microbial translocation to the liver, decreased β-glucuronidase and myeloperoxidase activities in the gut, decreased colonic macroscopic and microscopic damage, increased IL-10 and decreased IFNγ. | Mouse (TNBS induced colitis) | [ |
| κ-casein–derived glycomacropeptide | NA | Rag1-/-:increased body-weight gain, decreased colonic damage score and myeloperoxidase (MPO) activity, reduced percentage of CD4+ interferon IFNγ+ cells and increased IL-6 in MLN. Increased colonic expression of TNFα and IFNγ and increased IL-10 in MLN, by MLN. | Mouse (DSS induced colitis and Rag1-/-) | [ |
| bovine glycomacropeptide | NA | Decrease of inflammatory injury, as assessed by lower extension of necrosis and damage score, myeloperoxidase, alkaline phosphatase, inducible nitric oxide synthase, IL- 1β, TNFα, and IL-17. | Rat (TNBS induced colitis) | [ |
| Egg white hydrolysate | Aminopeptidase | Attenuated DSS-induced clinical symptoms, including weight loss, mucosal and submucosal inflammation, crypt distortion, and colon muscle thickening, and decreased intestinal permeability and increased mucin gene expression, reduced intestinal expression of pro-inflammatory cytokines TNFα, IL-6, IL-1β, IFNγ, IL-8, and IL-17. | Pig (DSS induced colitis) | [ |
| Soybean protein hydrolysate | Rhizopus oryzae neutral protease preparation | Increased number of IL-12+CD11b+ in spleens, increased cytotoxic activity of spleen cells, increased | Mouse | [ |
| Partially hydrolyzed whey protein | NA | Increased Breg and Treg in the spleen, increased IgA+ B-cells in the MLN, increased Th1, activated Treg and activated Th17 cells in the Peyer’s patches | Mouse | [ |
| LLDAQSAPLRVYVEELKP (from whey) | NA | Reduced acute allergic skin response, decreased whey-specific antibody levels, increased the percentages of CD11b+CD103+ dendritic cells and CD25+Foxp3+ T cells in the MLN. | Mouse | [ |
| Partial whey hydrolysate | NA | Reduced acute allergic skin response and mast cell degranulation after whey challenge, increased Foxp3+ regulatory T-cell numbers in the MLN. | Mouse | [ |
| oyster peptide-based enteral nutrition formula | Bromelain, pepsin, trypsin | Enhanced spleen lymphocyte proliferation and of NK cell activity | Mouse | [ |
| Casein hydrolysate | Trypsin | Phagocytosing capacity of phagocytic cells was increased | Mouse | [ |
| Milk protein hydrolysate | Improved the level of hemolysin in serum, and enhanced phagocytosis of macrophages. In ovalbumin-sensitized mice, the milk protein hydrolysates reduced IgE levels, reduced IL-4 in serum, reduced the release of histamine and bicarbonate in peritoneal mast cells, and enhanced TGFβ levels. | ICR mouse | [ | |
| Chum salmon oligopeptide preparation | Complex protease | Enhanced lymphocyte proliferation capacity increased number of plaque-forming cells, increased NK cell activity, increased percentage of CD4+ T helper (Th) cells in spleen and secretion of Th1 (IL-2, IFNγ) and Th2 (IL-5, IL-6) type cell cytokines. | ICR mouse | [ |
| Tuna cooking drip hydrolysate | Enzyme A and B | Increased weight of the spleen and thymus and enhanced the proliferation of splenocytes. Increased production of IL-10 and IL-2. Increased serum IgG1 and IgG2a levels. | Mouse | [ |
| Soy protein hydrolysate | Pepsin | Increased serum IgA and IgG levels | Rat | [ |
| Soy protein hydrolysate | Theroase, bioprase, Sumizyme FP | Total lymphocyte and granulocyte numbers were altered, and the numbers of CD11b+ cells and CD56+ cells increased. | Human | [ |
| Wheat gluten hydrolysate | NA | NK cell activity increased significantly | Human | [ |
| Fish protein hydrolysate (Amizate) | NA | No effects observed | Human | [ |
Figure 2Overview of immune effects induced by protein hydrolysates on the (A) intestinal epithelial cells; (B) intestinal immune cells; (C) mesenteric lymph nodes; (D) systemic immune system.
Figure 3Overview of mechanisms described in the literature via which peptides can exert immunomodulatory effects in the cell. Peptides can (A) directly stimulate receptors; (B) be taken up in the cell via a peptide transporter and interfere with inflammatory signaling pathways; or (C) be taken up into the cell via endocytosis and inhibit inflammatory signaling pathways.
Figure 4Summary of the application possibilities of protein hydrolysates. These hydrolysates are currently being used in sport nutrition, clinical nutrition, and infant formula, mainly because of their good digestibility and hypoallergenicity. Recent research indicates that specific protein hydrolysates could optimize the current products in multiple ways. Also, there is evidence that new protein hydrolysate products could be beneficial for specific target groups.
Figure 5Overview of T helper cell subsets and their interactions and their relation to specific diseases.